236 related articles for article (PubMed ID: 22207917)
1. Determinants of vaccine supply.
Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
[No Abstract] [Full Text] [Related]
2. The U.S. vaccine supply.
Hinman AR
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
[No Abstract] [Full Text] [Related]
3. Pharmaceuticals and medical devices: cost savings.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
[No Abstract] [Full Text] [Related]
4. The U.S. vaccine supply.
Schwartz HK
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
[No Abstract] [Full Text] [Related]
5. Safety, supply, and suits--litigation and the vaccine industry.
Kesselheim A
N Engl J Med; 2011 Apr; 364(16):1485-7. PubMed ID: 21506740
[No Abstract] [Full Text] [Related]
6. Vaccine supply, demand, and policy: a primer.
Muzumdar JM; Cline RR
J Am Pharm Assoc (2003); 2009; 49(4):e87-99. PubMed ID: 19589753
[TBL] [Abstract][Full Text] [Related]
7. The fragility of the U.S. vaccine supply.
Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
[No Abstract] [Full Text] [Related]
8. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
10. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
11. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
12. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
13. Pharmaceuticals and medical devices: FDA oversight.
; Berry MD
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
[No Abstract] [Full Text] [Related]
14. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
15. Wyeth Pharmaceutical's perspective on vaccine production.
Stiles GL
Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
[No Abstract] [Full Text] [Related]
16. FDA performance goals for approving drugs and biologics.
Miller JD
JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
[No Abstract] [Full Text] [Related]
17. Global perspectives on vaccine financing.
Berman S; Giffin RB
Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
[TBL] [Abstract][Full Text] [Related]
18. Drug shortage crisis resolution.
Duffy E
J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
[No Abstract] [Full Text] [Related]
19. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
20. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
